Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting

News provided by

Blueprint Medicines

Apr 08, 2015, 08:05 ET

CAMBRIDGE, Mass., April 8, 2015 /PRNewswire/ -- Blueprint Medicines today announced it will present new preclinical data on its drug candidate BLU-285 in gastrointestinal stromal tumors (GIST), as well as the discovery of new drug targets for a wide range of cancers, at the upcoming American Association for Cancer Research (AACR) annual meeting taking place April 18-22 in Philadelphia.

BLU-285 in GIST
BLU-285 is a highly selective and potent inhibitor of PDGFRα D842V and KIT Exon 17 mutants, which are receptor tyrosine kinase mutants known to play a key role in GIST. By inhibiting these mutants, BLU-285 targets previously unaddressed genomic drivers of the disease. The poster presentation at AACR marks the first time Blueprint Medicines researchers are presenting preclinical data demonstrating BLU-285's significant anti-tumor activity in treatment-resistant models of GIST.

  • Date & Time: Sunday, April 19 from 1-5 p.m. (EDT)
  • Presentation Title: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants
  • Presenter: Erica K. Evans, PhD, Director, Biology, Blueprint Medicines
  • Abstract Number: 791
  • Poster Board Number: 23
  • Location: Poster Section 32, Pennsylvania Convention Center

New Cancer Drug Targets
As part of a minisymposium on cancer genomics chaired by Blueprint Medicines' Chief Scientific Officer Christoph Lengauer, the company will present its discovery of new drug targets, using a proprietary computational approach to identify kinase fusions in cancer. In addition to paving the way for the discovery and development of novel therapies, these findings could have immediate implications for the diagnosis and treatment of cancer patients.

  • Date & Time: Sunday, April 19 from 3:15-5:15 p.m. (EDT)
  • Minisymposium Title: Cancer Genomics: Characterization, Evolution, and Function
  • Chair: Christoph Lengauer, PhD, MBA, Chief Scientific Officer, Blueprint Medicines
  • Location: Room 114, Pennsylvania Convention Center
  • Date & Time: Sunday, April 19 from 3:20-3:35 p.m. (EDT)
  • Presentation Title: The Landscape of Kinase Fusions in Cancer
  • Presenter: Nicolas Stransky, PhD, Senior Scientist, Computational Biology, Blueprint Medicines
  • Abstract Number: 954
  • Location: Room 114, Pennsylvania Convention Center

About Blueprint Medicines

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

CONTACT:

Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Relations:
Beth Keshishian
inVentiv Health PR
212-229-8417
[email protected] 

SOURCE Blueprint Medicines

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED